Your shopping cart is currently empty

5MPN is an orally active and selective inhibitor of 6-phosphofructokinase-2-kinase (PFKFB4) that competitively inhibits the F6P binding site and inhibits the proliferation of myeloma cells, and can be used in the study of myeloproliferative neoplasms.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $98 | - | In Stock | |
| 5 mg | $172 | - | In Stock | |
| 10 mg | $289 | - | In Stock | |
| 25 mg | $579 | - | In Stock | |
| 50 mg | $928 | - | In Stock | |
| 100 mg | $1,490 | - | In Stock | |
| 200 mg | $1,970 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $188 | - | In Stock |
| Description | 5MPN is an orally active and selective inhibitor of 6-phosphofructokinase-2-kinase (PFKFB4) that competitively inhibits the F6P binding site and inhibits the proliferation of myeloma cells, and can be used in the study of myeloproliferative neoplasms. |
| Targets&IC50 | PFKFB4:8.6 μM (Ki) |
| In vitro | In H460 cells, 5MPN (0-30 μM; 24 hours) is able to inhibit the expression of PFKFB4[2]. |
| In vivo | 5MPN (120 mg/kg; p.o.) effectively inhibits the growth of Lewis lung carcinomas (LLC) in C57BL/6 mice and H460 human lung adenocarcinoma xenografts in athymic mice, without impacting body weight. A decline in Ki67-positive cells within LLC xenografts suggests 5MPN interferes with cell cycle progression in vivo[1]. |
| Synonyms | 5-MPN |
| Molecular Weight | 305.33 |
| Formula | C15H19N3O4 |
| Cas No. | 47208-82-2 |
| Smiles | COc1cccc2c(NCCCCCO[N+]([O-])=O)ccnc12 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (262.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.